Literature DB >> 16516195

Constitutive signalling pathway activity in trabecular meshwork cells from glaucomatous eyes.

Xun Zhang1, Alison Schroeder, Eric M Callahan, Brad M Coyle, Nan Wang, Kristine A Erickson, Joel S Schuman, M Elizabeth Fini.   

Abstract

We recently described an IL-1-regulated stress response specific to the eye's aqueous outflow pathways that is diagnostic of glaucomas of diverse etiology. The goal of this study was to further identify IL-1-regulated signalling pathways in normal TM cells and determine whether their activity is altered in glaucomatous TM cells. Activity of the MAPK, p38, and JNK signalling pathways, represented by protein kinases ERK1/2, p38, and JNK-1, was followed by western blotting using antibodies specific for the active phosphorylated forms, after treatment of normal (N=5) or glaucomatous (N=5) cell lines by IL-1. Active forms of each of these kinases could be detected in normal and glaucomatous cells prior to treatment. When normal cells were stimulated with exogenous IL-1, an increase in activity of each of the kinases was observed. In contrast, treatment of glaucomatous cells with IL-1 resulted in little or no change in kinase activity. This difference was shown to be statistically significant by use of the paired two-tailed Student's t-test. Interference with IL-1 autocrine signalling in glaucomatous cell lines by treatment with IL-1 receptor antagonist (IL-1ra) had no effect on constitutive p38 or JNK activity (ERK was not examined). The results suggest that the MAPK, p38 and JNK signal transduction pathways are relatively unresponsive in glaucomatous cells as compared to normal cells. These results provide new information about the behaviour of glaucomatous TM cells, which may be important for understanding the pathophysiology of high-tension glaucoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16516195     DOI: 10.1016/j.exer.2005.11.001

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  7 in total

1.  Gene expression changes in steroid-induced IOP elevation in bovine trabecular meshwork.

Authors:  John Danias; Rosana Gerometta; Yongchao Ge; Lizhen Ren; Lampros Panagis; Thomas W Mittag; Oscar A Candia; Steven M Podos
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-07       Impact factor: 4.799

Review 2.  Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine.

Authors:  M Elizabeth Fini; Stephen G Schwartz; Xiaoyi Gao; Shinwu Jeong; Nitin Patel; Tatsuo Itakura; Marianne O Price; Francis W Price; Rohit Varma; W Daniel Stamer
Journal:  Prog Retin Eye Res       Date:  2016-09-22       Impact factor: 21.198

3.  Resveratrol prevents the expression of glaucoma markers induced by chronic oxidative stress in trabecular meshwork cells.

Authors:  Coralia Luna; Guorong Li; Paloma B Liton; Jianming Qiu; David L Epstein; Pratap Challa; Pedro Gonzalez
Journal:  Food Chem Toxicol       Date:  2008-11-06       Impact factor: 6.023

4.  Cross-talk between ciliary epithelium and trabecular meshwork cells in-vitro: a new insight into glaucoma.

Authors:  Natalie Lerner; Elie Beit-Yannai
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

5.  Effect of Myricetin on Primary Open-angle Glaucoma.

Authors:  Qing Yang; Ying Li; Lin Luo
Journal:  Transl Neurosci       Date:  2018-11-12       Impact factor: 1.757

6.  Cross-talk between TGF-beta1 and IL-6 in human trabecular meshwork cells.

Authors:  Paloma B Liton; Guorong Li; Coralia Luna; Pedro Gonzalez; David L Epstein
Journal:  Mol Vis       Date:  2009-02-11       Impact factor: 2.367

7.  Pro-fibrotic pathway activation in trabecular meshwork and lamina cribrosa is the main driving force of glaucoma.

Authors:  Alex Zhavoronkov; Evgeny Izumchenko; Riya R Kanherkar; Mahder Teka; Charles Cantor; Kebreten Manaye; David Sidransky; Michael D West; Eugene Makarev; Antonei Benjamin Csoka
Journal:  Cell Cycle       Date:  2016-06-17       Impact factor: 4.534

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.